Clinical trial
A Multicentric Phase 2 Study of Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-MUTATED Acute Myeloid Leukemia
NCT04867928 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentric Phase 2 Study of Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-MUTATED Acute Myeloid Leukemia
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 1, 2022
- Completion date
- January 31, 2025
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia, acute myeloid leukemia, in relapse, npm1 mutation